Zentalis Pharmaceuticals (ZNTL) Receivables - Other (2019 - 2023)

Zentalis Pharmaceuticals' Receivables - Other history runs 5 years deep, the most recent figure standing at $7.9 million for Q1 2023.

• On a quarterly basis, Receivables - Other rose 236.8% year-over-year to $7.9 million in Q1 2023; TTM through Mar 2023 was $7.9 million, a 236.8% increase from a year earlier, with the FY2022 full-year figure at $5.9 million, up 147.53% from the prior year.
• Receivables - Other improved to $7.9 million in Q1 2023 per ZNTL's latest filing, from $5.9 million in the prior quarter.
• Across five years, Receivables - Other topped out at $82.0 million in Q1 2020 and bottomed at $100000.0 in Q2 2020.
• The 5-year median for Receivables - Other is $2.4 million (2021), against an average of $9.5 million.
• Across the five-year window, Receivables - Other jumped 10150.0% in 2020 and tumbled 92.43% in 2022, its largest moves.
• Year by year, Receivables - Other stood at $200000.0 in 2019, then soared by 155.5% to $511000.0 in 2020, then soared by 364.38% to $2.4 million in 2021, then surged by 147.53% to $5.9 million in 2022, then surged by 34.63% to $7.9 million in 2023.
• Per Business Quant, the three latest ZNTL Receivables - Other figures stand at $7.9 million (Q1 2023), $5.9 million (Q4 2022), and $3.2 million (Q3 2022).